Takeda Pharmaceutical (TAK) FCF Payout Ratio Growth (1y) (2019 - 2026)
Takeda Pharmaceutical (TAK) FCF Payout Ratio Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 92.25 Bn | 90.38 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 36.33 Bn | 32.59 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.84 Bn | 30.89 Bn | 1.62 Bn | 15.81% |
| 4 | Takeda Pharmaceutical | 27.65 Bn | 23.59 Bn | 4.39 Bn | -130.26% |
| 5 | United Therapeutics | 22.75 Bn | 20.60 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.75 Bn | 22.75 Bn | - | - |
| 7 | Viatris | 20.60 Bn | 18.79 Bn | 1.16 Bn | 37.82% |
| 8 | Neurocrine Biosciences | 18.31 Bn | 16.99 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.73 Bn | 12.30 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.31 Bn | 10.15 Bn | 59.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -130.26% |
| Dec 31, 2025 | -5.91% |
| Sep 30, 2025 | 24.55% |
| Jun 30, 2025 | 9.02% |
| Mar 31, 2025 | 77.66% |
| Dec 31, 2024 | 52.52% |
| Sep 30, 2024 | 27.29% |
| Jun 30, 2024 | 35.83% |
| Mar 31, 2024 | -279.60% |
| Dec 31, 2023 | -128.00% |
| Sep 30, 2023 | 13.93% |
| Jun 30, 2023 | 7.34% |
| Mar 31, 2023 | 235.87% |
| Dec 31, 2022 | 10.72% |
| Sep 30, 2022 | -23.05% |
| Jun 30, 2022 | -51.93% |
| Mar 31, 2022 | 30.12% |
| Dec 31, 2021 | 35.97% |
| Sep 30, 2021 | -14.45% |
| Jun 30, 2021 | 14.78% |